Movatterモバイル変換

[0]ホーム
URL:

FR12C0052I1 - - Google Patents

Info

Publication number
FR12C0052I1
FR12C0052I1FR12C0052CFR12C0052I1FR 12C0052 I1FR12C0052 I1FR 12C0052I1FR 12C0052 CFR12C0052 CFR 12C0052CFR 12C0052 I1FR12C0052 I1FR 12C0052I1
Authority
FR
France
Prior art keywords
administering
therapy
prevention
patient
rapid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0052(I1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR12C0052I1publicationCriticalpatent/FR12C0052I1/fr
Application filedfiledCritical
Application grantedgrantedCritical
Publication of FR12C0052I2publicationCriticalpatent/FR12C0052I2/en
Activelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Methods for the prevention, treatment or management of sexual dysfunction, as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.
FR12C0052C1999-09-032012-08-29 USE OF DAPOXETINE, A FAST-ACTING SELECTIVE SEROTONIN REUPTAKE INHIBITOR, TO TREATE SEXUAL DYSFUNCTIONActiveFR12C0052I2 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US15243599P1999-09-031999-09-03
PCT/US2000/020788WO2001017521A1 (en)1999-09-032000-08-22Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Publications (2)

Publication NumberPublication Date
FR12C0052I1true FR12C0052I1 (en)2012-05-10
FR12C0052I2 FR12C0052I2 (en)2013-08-16

Family

ID=22542905

Family Applications (1)

Application NumberTitlePriority DateFiling Date
FR12C0052CActiveFR12C0052I2 (en)1999-09-032012-08-29 USE OF DAPOXETINE, A FAST-ACTING SELECTIVE SEROTONIN REUPTAKE INHIBITOR, TO TREATE SEXUAL DYSFUNCTION

Country Status (34)

CountryLink
US (4)US7718705B1 (en)
EP (3)EP1225881B1 (en)
JP (1)JP3194734B2 (en)
KR (1)KR100719977B1 (en)
CN (1)CN1222283C (en)
AT (1)ATE318135T1 (en)
AU (1)AU762934B2 (en)
BE (1)BE2012C040I2 (en)
BG (1)BG65677B1 (en)
BR (1)BR0014166A (en)
CA (1)CA2383785C (en)
CY (1)CY2012028I1 (en)
CZ (1)CZ299712B6 (en)
DE (2)DE60026146T2 (en)
DK (1)DK1225881T3 (en)
EA (1)EA004101B1 (en)
EE (1)EE05315B1 (en)
ES (2)ES2256032T3 (en)
FR (1)FR12C0052I2 (en)
HK (1)HK1047545B (en)
HR (1)HRP20020189A2 (en)
HU (1)HU229150B1 (en)
IL (2)IL148159A0 (en)
LU (1)LU92204I2 (en)
MX (1)MXPA02001811A (en)
MY (1)MY125490A (en)
NO (2)NO330562B1 (en)
NZ (1)NZ517038A (en)
PL (1)PL211402B1 (en)
SI (1)SI1225881T1 (en)
TW (3)TWI367751B (en)
UA (1)UA75580C2 (en)
WO (1)WO2001017521A1 (en)
ZA (1)ZA200201407B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6403597B1 (en)1997-10-282002-06-11Vivus, Inc.Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2383785C (en)*1999-09-032009-02-17Eli Lilly And CompanyMethods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
JP4377585B2 (en)2001-03-162009-12-02ディーエムアイ バイオサイエンシズ インコーポレイテッド Method of ejaculation delay
EE200300478A (en)2001-03-292003-12-15Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
CA2410966C (en)*2002-11-012005-11-22Craig J. HudsonSexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en)*2003-07-112003-07-24Jakov VaismanTreatment of premature ejaculation
GB0318706D0 (en)*2003-08-082003-09-10Pfizer LtdSelective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (en)2009-03-312010-10-07Ratiopharm Gmbh Tablets containing dapoxetine and dry processing for their preparation
DE102009058321A1 (en)2009-12-152011-06-16Ratiopharm Gmbh Orodispersible tablet containing dapoxetine
EP2591773A4 (en)2010-07-062014-11-26Navipharm Co LtdTime-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
RU2463033C2 (en)*2010-08-062012-10-10Василий Федорович ПятинMethod of treating premature ejaculation
CN103100085A (en)*2011-11-092013-05-15上海兰蒂斯生物医药科技有限公司Pharmaceutical composition
CN103130660B (en)*2011-11-252014-09-17厦门福满药业有限公司Acidic salt and crystal of dapoxetine and preparation method of crystal
WO2014042416A1 (en)*2012-09-132014-03-20주식회사 씨티씨바이오Oral composition containing dapoxetin-free base
KR101432905B1 (en)2012-12-112014-08-21가톨릭대학교 산학협력단Pharmaceutical composition for treating genetic pain comprising dapoxetine
US20160101093A1 (en)*2013-05-212016-04-14Jason B. WynbergMethods for the treatment of premature ejaculation
CN103735525B (en)*2014-02-122015-05-06江苏仁寿药业有限公司Dapoxetine tablets and preparation method thereof
WO2016025541A1 (en)*2014-08-122016-02-18Tianxin WangTherapeutical methods, formulations and nutraceutical formulations
US20180071269A1 (en)2015-08-122018-03-15Tianxin WangTherapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en)*2016-11-302018-06-07Wang tian xinTherapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en)2016-12-302018-07-23Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113143879A (en)*2021-05-072021-07-23苏州康恒研新药物技术有限公司Preparation method of dapoxetine hydrochloride sustained release tablet
CN113181127A (en)*2021-05-072021-07-30苏州康恒研新药物技术有限公司Preparation method of dapoxetine hydrochloride pellet tablets
US11977085B1 (en)2023-09-052024-05-07Elan EhrlichDate rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3536809A (en)1969-02-171970-10-27Alza CorpMedication method
US3598123A (en)1969-04-011971-08-10Alza CorpBandage for administering drugs
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916899A (en)1973-04-251975-11-04Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
US4018895A (en)*1974-01-101977-04-19Eli Lilly And CompanyAryloxyphenylpropylamines in treating depression
US4194009A (en)*1974-01-101980-03-18Eli Lilly And CompanyAryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en)*1974-01-101982-02-02Eli Lilly And CompanyArloxyphenylpropylamines
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en)*1978-06-221980-06-10Eli Lilly And Company1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en)*1980-10-311982-05-11Eli Lilly And CompanyTreatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en)1984-10-301993-07-14Elan Corp PlcControlled release powder and process for its preparation
US5135947A (en)1987-04-091992-08-04Eli Lilly And Company1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en)1988-05-311989-09-12Top Laboratories, Inc.Low-dosage sublingual aspirin
US5082667A (en)1988-06-071992-01-21Abbott LaboratoriesSolid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en)1988-07-211991-12-17G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en)1989-01-061992-05-19Norden Michael JMethod for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (en)1989-03-221991-07-25Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US4940731A (en)1989-08-301990-07-10Pfizer Inc.Method of treating premature ejaculation using sertraline
US5120548A (en)1989-11-071992-06-09Merck & Co., Inc.Swelling modulated polymeric drug delivery device
US5733566A (en)1990-05-151998-03-31Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
US5589511A (en)1990-08-131996-12-31Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en)1991-07-121992-09-29Crenshaw Roger TMethod for treating premature ejaculation
US5151488A (en)*1991-11-121992-09-29The Mead CorporationLiquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en)1992-08-131993-09-28Pfizer Inc.Sertraline polymorph
US5292962A (en)1992-12-111994-03-08Eli Lilly And CompanyIntermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en)1993-01-251997-01-07Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en)*1993-02-011993-06-03Lilly Co EliPharmaceutical treatments.
US5276042A (en)1993-04-161994-01-04Crenshaw Roger TTreatment of premature ejaculation
IT1264965B1 (en)1993-11-121996-10-17Giorgio Cavallini USE OF ALFA 1-BLOCCANTI IN THE TREATMENT OF EARLY EJACULATION
EP0978282B1 (en)1994-04-222005-12-14Pentech Pharmaceuticals, Inc.Sublingual composition containing apomorphine for diagnosing functional impotence
CA2134038C (en)1994-06-161997-06-03David Taiwai WongPotentiation of drug response
IT1270594B (en)1994-07-071997-05-07Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5457121A (en)1994-09-021995-10-10Eli Lilly And CompanyCis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en)1994-09-141997-01-28Pfizer Inc.Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en)1994-10-201997-04-16Lilly Co EliTreatment of disorders with duloxetine
EP0714663A3 (en)1994-11-281997-01-15Lilly Co Eli Potentiation of a drug by a serotonin 1A receptor antagonist
US5576321A (en)1995-01-171996-11-19Eli Lilly And CompanyCompounds having effects on serotonin-related systems
US5627196A (en)1995-01-171997-05-06Eli Lilly And CompanyCompounds having effects on serotonin-related systems
US5789402A (en)1995-01-171998-08-04Eli Lilly CompanyCompounds having effects on serotonin-related systems
US5614523A (en)1995-01-171997-03-25Eli Lilly And CompanyCompounds having effects on serotonin-related systems
WO1996024353A1 (en)1995-02-101996-08-15Eli Lilly And CompanyMethods of treating or preventing psychiatric disorders
US5624677A (en)1995-06-131997-04-29Pentech Pharmaceuticals, Inc.Controlled release of drugs delivered by sublingual or buccal administration
US6100275A (en)1995-10-132000-08-08Neurosearch A/S8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use
US5758911A (en)*1996-02-071998-06-02Northrop Grumman CorporationLinear motion wind driven power plant
US5897864A (en)1996-05-231999-04-27Cohen; Alan J.Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en)1996-06-141998-12-08Eli Lilly And CompanyInhibition of serotonin reuptake
US5912256A (en)1996-06-201999-06-15Eli Lilly And CompanyCompounds having effects on serotonin-related systems
US5830500A (en)*1996-07-221998-11-03Pentech Pharmaceuticals, Inc.Low dose fluoxetine tablet
US5672612A (en)1996-09-091997-09-30Pentech Pharmaceuticals, Inc.Amorphous paroxetine composition
US6638948B1 (en)1996-09-092003-10-28Pentech Pharmaceuticals, Inc.Amorphous paroxetine composition
US5910319A (en)1997-05-291999-06-08Eli Lilly And CompanyFluoxetine enteric pellets and methods for their preparation and use
NZ513456A (en)1997-07-012003-02-28PfizerSertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
AU724635B2 (en)1997-07-012000-09-28Pfizer Products Inc.Gelatine encapsulated solution dosage forms of sertraline
CN1494899A (en)1997-07-012004-05-12�Ʒ� Extended-release formulations of sertraline
FR2765483B1 (en)*1997-07-042000-02-04Philippe Gorny MEDICINE FOR TREATING ERECTILE DYSFUNCTIONS
US6037360A (en)1997-10-282000-03-14Vivus, IncorporatedAdministration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en)1997-10-281999-07-13Vivus, IncorporatedLocal administration of pharmacologically active agents to treat premature ejaculation
US6228864B1 (en)1997-10-282001-05-08Vivus, Inc.Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
UA66370C2 (en)1997-12-162004-05-17Lilly Co EliArylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (en)1998-04-092000-09-29Pfizer Prod Inc AZABICICLIC LEAGUES OF RECEIVERS 5HT1
US6303627B1 (en)1998-06-192001-10-16Eli Lilly And CompanyInhibitors of serotonin reuptake
CA2335336A1 (en)1998-06-191999-12-23James Edmund AudiaInhibition of serotonin reuptake
FR2781671A1 (en)1998-07-282000-02-04Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING SEROTONIN RECAPTURE INHIBITOR AND THERAPEUTIC USE THEREOF
US6150376A (en)1998-08-052000-11-21Georgetown UniversityBi- and tri-cyclic aza compounds and their uses
WO2000021521A2 (en)1998-10-132000-04-20Pfizer Products Inc.Sertraline oral concentrate
EP1180021A4 (en)*1999-05-062005-01-19Pentech Pharmaceuticals IncRegimen and kit for amelioration of premature ejaculation
US20010003120A1 (en)*1999-05-142001-06-07M. D. Robert HinesMethod for treating erectile dysfunction
CA2383785C (en)*1999-09-032009-02-17Eli Lilly And CompanyMethods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Also Published As

Publication numberPublication date
HK1047545B (en)2006-09-22
IL148159A0 (en)2002-09-12
KR100719977B1 (en)2007-05-21
CY2012028I2 (en)2017-04-05
AU762934B2 (en)2003-07-10
DE122009000036I1 (en)2009-11-05
MY125490A (en)2006-08-30
KR20020025252A (en)2002-04-03
US20140221497A1 (en)2014-08-07
NO20021035L (en)2002-05-02
EP1225881A1 (en)2002-07-31
MXPA02001811A (en)2002-08-06
WO2001017521A1 (en)2001-03-15
TWI312678B (en)2009-08-01
BR0014166A (en)2002-05-14
HUP0202687A2 (en)2002-12-28
AU6891100A (en)2001-04-10
NZ517038A (en)2003-04-29
CA2383785C (en)2009-02-17
CZ2002784A3 (en)2002-09-11
NO20021035D0 (en)2002-03-01
PL364924A1 (en)2004-12-27
NO2012015I2 (en)2013-08-26
HRP20020189A2 (en)2004-02-29
TW201018459A (en)2010-05-16
SI1225881T1 (en)2006-06-30
US20050215617A1 (en)2005-09-29
ES2393582T3 (en)2012-12-26
DE122009000036I2 (en)2010-05-06
HK1091418A1 (en)2007-01-19
BG106461A (en)2002-12-29
CA2383785A1 (en)2001-03-15
DK1225881T3 (en)2006-06-12
EP1889614A3 (en)2010-09-22
EP1671628A1 (en)2006-06-21
EE05315B1 (en)2010-08-16
DE60026146T2 (en)2006-08-17
NO2012015I1 (en)2012-09-11
US7718705B1 (en)2010-05-18
JP2001089394A (en)2001-04-03
NO330562B1 (en)2011-05-16
CZ299712B6 (en)2008-10-29
HUP0202687A3 (en)2006-03-28
EA004101B1 (en)2003-12-25
DE60026146D1 (en)2006-04-27
TWI367751B (en)2012-07-11
CY2012028I1 (en)2017-04-05
EA200200324A1 (en)2002-08-29
IL148159A (en)2009-11-18
HK1047545A1 (en)2003-02-28
CN1387432A (en)2002-12-25
LU92204I2 (en)2013-07-23
US20050261377A1 (en)2005-11-24
EP1225881B1 (en)2006-02-22
FR12C0052I2 (en)2013-08-16
PL211402B1 (en)2012-05-31
EE200200107A (en)2003-04-15
EP1889614A2 (en)2008-02-20
ATE318135T1 (en)2006-03-15
BE2012C040I2 (en)2019-10-16
BG65677B1 (en)2009-06-30
JP3194734B2 (en)2001-08-06
UA75580C2 (en)2006-05-15
HU229150B1 (en)2013-09-30
ES2256032T3 (en)2006-07-16
TW200524582A (en)2005-08-01
CN1222283C (en)2005-10-12
EP1671628B1 (en)2012-10-03
ZA200201407B (en)2003-07-30

Similar Documents

PublicationPublication DateTitle
BE2012C040I2 (en)
IL151164A0 (en)Azacyclic compounds for use in the treatment of serotonin related diseases
ES2165990T3 (en) THIP FOR THE TREATMENT OF SLEEP DISORDERS.
BR0316753A (en) Treatment method for sexual dysfunction
WO2004110380A3 (en)Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
ZA200109322B (en)A new use for deferiprone.
MXPA03004288A (en)Treatment of anti-depression drug-induced sexual dysfunction with apomorphine.
WO1999065475A3 (en)Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
PT1183046E (en) AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF CARDIOVASCULAR DISEASES
CY1118068T1 (en) THE USE OF DOXOXETINE, A SPEED-LAUNCHED SELECTIVE OPTIONAL INHIBITOR FOR SEPOTONINE TREATMENT FOR THERAPEUTIC ADMINISTRATION
PA8505301A1 (en) METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5 CETO-2-N- PROPILAMINE - TETRAHYDROTETRALINE
UA33498A (en)Method for treatment of resistant forms of schizophrenia
UY26405A1 (en) METHOD FOR TREATING PARKINSON&#39;S EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETRALINE.
ECSP003725A (en) METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) -5- CETO-2-N, N-D1-N-PROPILAMINO-TETRAHIDROTETRALINA
[8]ページ先頭
©2009-2025 Movatter.jp